North America Spearheading the Global Kidney Cancer Drugs Market

North America Spearheading the Global Kidney Cancer Drugs Market

North America Spearheading the Global Kidney Cancer Drugs Market

Kidney Cancer Drugs Market (Major Drugs: Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient (Pazopanib)) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020


Kidney cancer is considered to be one of the 10 most common cancers affecting men and women across the globe. While the risk of kidney cancer is higher in men than in women, there are numerous factors that determine the risk of cancer. The two main types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC), and kidney cancer drugs are generally administered to patients of stage four, advanced RCC.

Browse Full Global Kidney Cancer Drugs Market Report With Complete TOC @ http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html


According to the American Cancer Society, in the year 2015, approximately 61,560 new cases of kidney cancer will be registered in the United States alone, of which 23,290 will be women and 38,270 will be men. Out of these, around 14,080 people will die from the disease in 2015, of which 5,010 will be women and 9,070 will be men.

The U.S. National Cancer Institute states that kidney cancer is more common among American Indian, African American, and Alaska Native populations. This makes North America a rather large and lucrative market for kidney cancer drugs.

Votrient: Most promising commercially available kidney cancer drug

There are a number of kidney cancer drugs that are prescribed, used, and commercially available today. Some of the major brands are Votrient (Pazopanib), Inlyta (Axitinib), Proleukin (Aldesleukin), Afinitor (Everolimus), Sutent (Sunitinib), Nexavar (Sorafenib), Torisel (Temsirolimus), and Avastin (Bevacizumab).

Of these, Sutent (Sunitinib) dominated the kidney cancer...

Similar Essays